XAF1 and central nervous system cancer: The luciferase analysis showed that WZY-321 treatment did not enhance XAF1 promotor activity in the glioma cells (Fig. 1F), suggesting that WZY-321 could increase XAF1 expression at posttranscriptional level in glioma cells.